Healing by Proxy: Newly Discovered Drug Elenagen May Treat Cancer and Inflammation Through Indirect Action
June 14, 2024
Breakthroughs and challenges in therapeutic cancer vaccines: A new era of hope?
June 20, 2024Elenagen's indirect mechanism offers new hope in cancer and inflammation treatment
In the article "Healing by Proxy: Newly Discovered Drug May Treat Cancer and Inflammation Through Indirect Action," eCancer highlights the collaborative research between the University of Camerino and CureLab Oncology. The study reveals that Elenagen, a circular DNA encoding the p62/SQSTM1 protein, reprograms aged, pro-inflammatory stem cells into youthful, anti-inflammatory ones. This transformation leads to the secretion of beneficial factors that mimic Elenagen's effects, offering potential treatments for cancer and age-related inflammatory diseases.
eCancer is a reputable platform dedicated to oncology news and education. Its coverage of Elenagen's novel mechanism underscores the significance of CureLab Oncology's research in developing innovative therapies. The article emphasizes the potential of Elenagen to revolutionize treatments for cancer and inflammation, highlighting CureLab Oncology's commitment to advancing medical science.
